GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (FRA:UQ1) » Definitions » Cyclically Adjusted Price-to-FCF

uniQure NV (FRA:UQ1) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


uniQure NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for uniQure NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Cyclically Adjusted Price-to-FCF Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

uniQure NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of uniQure NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, uniQure NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where uniQure NV's Cyclically Adjusted Price-to-FCF falls into.



uniQure NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

uniQure NV's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, uniQure NV's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.989/126.4000*126.4000
=-0.989

Current CPI (Dec. 2023) = 126.4000.

uniQure NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.542 99.390 -0.689
201406 -0.718 99.240 -0.915
201409 -0.551 99.960 -0.697
201412 -0.824 99.050 -1.052
201503 -0.769 99.750 -0.974
201506 1.740 100.230 2.194
201509 -0.071 100.500 -0.089
201512 -0.968 99.730 -1.227
201603 -0.640 100.310 -0.806
201606 -0.867 100.260 -1.093
201609 -0.972 100.570 -1.222
201612 -0.748 100.710 -0.939
201703 -0.501 101.440 -0.624
201706 -0.716 101.370 -0.893
201709 -0.536 102.030 -0.664
201712 -0.520 101.970 -0.645
201803 -0.565 102.470 -0.697
201806 -0.438 103.100 -0.537
201809 -0.481 103.950 -0.585
201812 -0.441 103.970 -0.536
201903 -0.650 105.370 -0.780
201906 -0.595 105.840 -0.711
201909 -0.541 106.700 -0.641
201912 -0.576 106.800 -0.682
202003 -0.733 106.850 -0.867
202006 -0.634 107.510 -0.745
202009 -0.704 107.880 -0.825
202012 -0.733 107.850 -0.859
202103 -0.834 108.870 -0.968
202106 7.325 109.670 8.442
202109 -0.881 110.790 -1.005
202112 -0.953 114.010 -1.057
202203 -0.580 119.460 -0.614
202206 -0.411 119.050 -0.436
202209 -1.144 126.890 -1.140
202212 -1.203 124.940 -1.217
202303 -1.588 124.720 -1.609
202306 -1.125 125.830 -1.130
202309 0.730 127.160 0.726
202312 -0.989 126.400 -0.989

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


uniQure NV  (FRA:UQ1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


uniQure NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of uniQure NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV (FRA:UQ1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (FRA:UQ1) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

uniQure NV (FRA:UQ1) Headlines

No Headlines